Ara
Toplam kayıt 3, listelenen: 1-3
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR +, HER2-metastatic breast cancer
(2022)
Purpose Resistance to endocrine therapy poses a major clinical challenge for patients with hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). We ...
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
(2021)
nextMONARCH investigated abemaciclib monotherapy and abemaciclib combined with tamoxifen. Patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (MBC) were treated ...